| 商品名称 | Doxirobe |
|---|---|
| 适用类别 | Veterinary |
| 治疗领域 | |
| 通用名/非专利名称 | doxycycline |
| 活性成分 | doxycycline |
| 产品号 | EMEA/V/C/000044 |
| 患者安全信息 | No |
| 许可状态 | Withdrawn |
| ATC编码 | QJ01AA02 |
| 是否额外监管 | No |
| 是否仿制药或hybrid药物 | No |
| 是否生物类似药 | No |
| 是否附条件批准 | No |
| 是否特殊情形 | No |
| 是否加速审评 | No |
| 是否罕用药 | No |
| 上市许可日期 | 1999/09/16 |
| 上市许可开发者/申请人/持有人 | Pfizer Limited |
| 人用药物治疗学分组 | |
| 兽用药物治疗学分组 | Antibacterials for systemic use |
| 欧盟委员会决定日期 | 2003/12/01 |
| 修订号 | 4 |
| 治疗适应症 | Treatment of periodontal disease in dogs.Periodontal pocket probing depths >=4 mm are evidence of disease that may be responsive to treatment with the Doxirobe Gel. Use of this product as directed should result in attachment level gains, periodontal pocket depth reductions, local antimicrobial effect and improved gingival health. Noticeable improvements in these parameters should be evident within 2-4 weeks following treatment. The response in individual dogs is dependent on the severity of the condition and rigor of adjunctive therapy. |
| 适用物种 | Dogs |
| 兽用药物ATC编码 | QJ01AA02 |
| 首次发布日期 | 2003/12/01 |
| 最后更新日期 | 2004/09/16 |
| 产品说明书 | |
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/veterinary/EPAR/doxirobe |